An amended Form 4/A was filed on November 19, 2026 by Glenn P. Muir, a director of Neuronetics, Inc. (NASDAQ:STIM), correcting a footnote error in the original Form 4 filed November 18, 2026, and reporting his purchase of 175,000 shares of common stock on November 16, 2026.
Key Highlights
- Reporting person: Glenn P. Muir, identified as a Director of Neuronetics, Inc.
- Transaction: Acquisition (Code A) of 175,000 shares of common stock on November 16, 2026.
- Weighted average price: $1.31 per share, with individual transaction prices ranging from $1.25 to $1.385 per share.
- Post-transaction ownership: 576,816 shares of common stock held directly following the reported transaction.
- Amendment purpose: The original filing dated November 18, 2026 "inadvertently refereed to shares sold in the footnote describing the average weighted price" and was corrected to refer to a purchase.
- Price detail availability: Muir has undertaken to provide full information on shares purchased at each separate price within the range upon request to SEC staff, the issuer, or any stockholder.
Director Muir's November 16 Open-Market Purchase and Footnote Correction
According to the amended filing, Glenn P. Muir, a director of Neuronetics, Inc., acquired 175,000 shares of Neuronetics common stock on November 16, 2026. The transaction was recorded with an acquisition code (A), and the reported price of $1.31 represents a weighted average across multiple purchases. The filing states that the per-share prices ranged from $1.25 to $1.385 across those individual transactions.
The Form 4/A was submitted to correct a specific error in the November 18, 2026 original filing. As stated in the explanation of responses, the prior form "inadvertently refereed to shares sold in the footnote describing the average weighted price," and the amendment corrects that reference to a purchase. No other changes to the transaction data appear to have been made in the amendment. The filing was signed by Patrick Devine as Attorney-in-Fact on November 19, 2026.
Following the reported transaction, Muir's direct beneficial ownership in Neuronetics common stock stood at 576,816 shares, according to the filing. No derivative securities transactions were reported in Table II of the form. The filing does not indicate that the transaction was made pursuant to a Rule 10b5-1(c) plan, as that checkbox was not selected.
What Was Disclosed
Neuronetics director Glenn P. Muir filed an amended Form 4/A disclosing a November 16, 2026 purchase of 175,000 common shares at a weighted average price of $1.31, and correcting a footnote in the original filing that incorrectly referenced a sale rather than a purchase.



Please wait processing your request...